Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02662764
Recruitment Status : Completed
First Posted : January 26, 2016
Results First Posted : August 8, 2018
Last Update Posted : August 8, 2018
Sponsor:
Information provided by (Responsible Party):
AcelRx Pharmaceuticals, Inc.

Brief Summary:
Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg

Condition or disease Intervention/treatment Phase
Moderate-to-severe Acute Pain Drug: Zalviso™ 15 mcg Phase 3

Detailed Description:
320 adult postoperative in-patients, who met all study entry requirements, and were expected to require opioid analgesia for at least 24 hours, and up to 72 hours, after surgery were enrolled. Patients used the Zalviso™ (sufentanil sublingual tablet system) 15 mcg to self-administer a tablet of study drug as needed for pain. The System was evaluated for usability and functionality for up to 72 hours.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
Actual Study Start Date : September 28, 2016
Actual Primary Completion Date : April 14, 2017
Actual Study Completion Date : May 5, 2017


Arm Intervention/treatment
Experimental: Zalviso™ 15 mcg
Zalviso™(sufentanil sublingual tablet system) 15 mcg
Drug: Zalviso™ 15 mcg
Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
Other Name: Zalviso™ (sufentanil sublingual tablet system) 15 mcg




Primary Outcome Measures :
  1. Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System [ Time Frame: Up to 72 hours ]
  2. Percentage of Patients, if Any, With Tablets Dispensed But Not Requested [ Time Frame: Up to 72 hours ]
  3. Percentage of Patients, if Any, With Tablet Dispensed When the Zalviso System Was in Lockout [ Time Frame: Up to 72 hours ]
  4. Percentage of Patients With Misplaced Tablet(s) [ Time Frame: Up to 72 hours ]
  5. Number of Misplaced Tablets (i.e., Tablet Found Outside the Patient's Mouth) [ Time Frame: Up to 24 hours ]
  6. Percentage of Patients Who Experienced Either a System-generated Error or a Misplaced Tablet (i.e., a Dispense Failure) [ Time Frame: Up to 72 hours ]
  7. Number of Zalviso System Notifications to the Nurse to Retrain Patient to Not Pull Down on the Controller While Dosing [ Time Frame: Up to 72 hours ]
  8. Percentage of Patients Who Experienced Either a System-generated Error or a Misplaced Tablet That Caused an Analgesic Gap [ Time Frame: Up to 72 hours ]
  9. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 24 Hours as "Good" or "Excellent" [ Time Frame: Up to 24 hours ]
  10. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 48 Hours as "Good" or "Excellent" [ Time Frame: Up to 48 hours ]
  11. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 72 Hours as "Good" or "Excellent" [ Time Frame: Up to 72 hours ]
  12. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Poor" at 24 Hours [ Time Frame: Up to 24 hours ]
  13. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Fair" at 24 Hours [ Time Frame: Up to 24 hours ]
  14. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Good" at 24 Hours [ Time Frame: Up to 24 hours ]
  15. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Excellent" at 24 Hours [ Time Frame: Up to 24 hours ]
  16. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Poor" [ Time Frame: Up to 48 hours ]
  17. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Fair" [ Time Frame: Up to 48 hours ]
  18. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Good" [ Time Frame: Up to 48 hours ]
  19. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Excellent" [ Time Frame: Up to 48 hours ]
  20. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Poor" [ Time Frame: Up to 72 hours ]
  21. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Fair" [ Time Frame: Up to 72 hours ]
  22. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Good" [ Time Frame: Up to 72 hours ]
  23. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Excellent" [ Time Frame: Up to 72 hours ]
  24. Percentage of Healthcare Professionals (HCPs) Who Rated the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 24 Hours as "Good" or "Excellent" [ Time Frame: Up to 24 hours ]
  25. Percentage of Healthcare Professionals (HCPs) Who Rate the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 48 Hours as "Good" or "Excellent" [ Time Frame: Up to 48 hours ]
  26. Percentage of Healthcare Professionals (HCPs) Who Rated the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 72 Hours as "Good" or "Excellent" [ Time Frame: Up to 72 hours ]
  27. Percentage of Healthcare Professional (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Poor" at 24 Hours [ Time Frame: Up to 24 hours ]
  28. Percentage of Healthcare Professional Global Assessment (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Fair" at 24 Hours [ Time Frame: Up to 24 hours ]
  29. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Good" at 24 Hours [ Time Frame: Up to 24 hours ]
  30. Percentage of Healthcare Professional (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Excellent" at 24 Hours [ Time Frame: Up to 24 hours ]
  31. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Poor" [ Time Frame: Up to 48 hours ]
  32. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Fair" [ Time Frame: Up to 48 hours ]
  33. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA )at 48 Hours as "Good" [ Time Frame: Up to 48 hours ]
  34. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Excellent" [ Time Frame: Up to 48 hours ]
  35. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Poor" [ Time Frame: Up to 72 hours ]
  36. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Fair" [ Time Frame: Up to 72 hours ]
  37. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Good" [ Time Frame: Up to 72 hours ]
  38. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Excellent" [ Time Frame: Up to 72 hours ]
  39. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia Over the 24-hour Study Period [ Time Frame: Up to 24 hours ]
  40. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia After the 24-hour Study Period and Prior to or During the 48 Hour Study Period [ Time Frame: Up to 48 hours ]
  41. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia Prior to or During the 72 Hour Study Period [ Time Frame: Up to 72 hours ]
  42. Time-weighted Summed Pain Intensity Difference (SPID) Over the 24-hour Study Period (SPID24) [ Time Frame: Up to 24 hours ]
    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points throughout the 24 hour period. The time-weighted SPID24 is the time-weighted summed PID over the 24-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity.The scores ranged from - 72 to 204.

  43. Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48) Study Period [ Time Frame: Up to 48 hours ]
    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points and throughout the 48 hour period. The time-weighted SPID48 is the time-weighted summed PID over the 48-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity.The scores ranged from -144 to 408.

  44. Time-weighted Summed Pain Intensity Difference (SPID) Over the 72-hour Study Period (SPID-72) Study Period [ Time Frame: Up to 72 hours ]
    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points throughout the 72 hour period. The time-weighted SPID72 is the time-weighted summed PID over the 72-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity. The scores ranged from -239 to 624.

  45. Total Pain Relief (TOTPAR) Over the 24-hour Study Period (TOTPAR24) [ Time Frame: Up to 24 hours ]
    Total pain relief over the 24-hour study period. A higher TOTPAR score means a greater relief in pain. Range of scores was from 0.00 to 96.00.

  46. Total Pain Relief (TOTPAR) Over the 48-hour Study Period (TOTPAR48) [ Time Frame: Up to 48 hours ]
    Total pain relief over the 48-hour study period. A higher TOTPAR score means a greater relief in pain. Range of scores was from 0.00 to 192.00.

  47. Total Pain Relief (TOTPAR) Over the 72-hour Study Period (TOTPAR72) [ Time Frame: Up to 72 hours ]
    Total pain relief over the 72-hour study period. A higher TOTPAR means a greater relief in pain. Range of scores was from 0.00 to 288.00.

  48. Pain Intensity (PI) at Each Evaluation Time Point [ Time Frame: Up to 72 hours ]
    At protocol-specified time points, the patient is asked to self-record his/her current level of pain on an 11-point numerical rating scale where 0 equals no pain and 10 equals the worst possible pain.

  49. Pain Intensity Difference (PID) at Each Evaluation Time Point [ Time Frame: Up to 72 hours ]
    The PID at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. The higher the PID score, the lower the pain intensity. The scores ranged from - 239 to 624.

  50. Pain Relief (PR) at Each Evaluation Time Point [ Time Frame: Up to 72 hours ]
    At protocol-specified time points, the patient is asked to self-record his/her current level of pain relief on 5-point numerical rating scale where 0 equaled no pain relief and 4 equaled complete pain relief. The baseline score references the baseline pain intensity score and the following timepoints reference pain relief scores.

  51. Patient Usability Questionnaire (PUQ) [ Time Frame: Up to 72 hours ]
    Questionnaire completed by patients at the end of his/her participation in the study regarding the usability of Zalviso.

  52. Nurse Usability Questionnaire (NUQ) [ Time Frame: Up to 72 hours ]
    Questionnaire regarding the usability of Zalviso completed by HCPs who had set up at least 5 Zalviso Systems for patients

  53. Number of Study Drug Doses Used [ Time Frame: Up to 72 hours ]
  54. Average Hourly Use of Study Drug [ Time Frame: Up to 72 hours ]
    Average number of study drug doses used per hour, adjusting by treatment exposure time and study period

  55. Average Inter-dosing Interval (in Minutes) [ Time Frame: Up to 72 hours ]
  56. Total Amount of Supplemental Morphine (mg) Utilized [ Time Frame: Up to 72 hours ]
    Supplemental opioid medication (2 mg IV morphine) was allowed in the first 30 minutes after the first on-demand dose of study drug had been administered, if necessary, to keep a patient comfortable. Otherwise, supplemental opioid medication (2 mg IV morphine, no more frequently than hourly) was allowed for pain due to ambulation or with the initiation of passive range of motion therapy throughout the remainder of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients who were 18 years of age or older.
  2. Patients who were scheduled to undergo surgery under general or spinal anesthesia that does not include intrathecal opioids during the operation.
  3. Patients classified as American Society of Anesthesiologists (ASA) class I - III (Appendix I).
  4. Female patients of childbearing potential must have been using an effective method of birth control at the time of screening visit and for 30 days following the end of the study period. Acceptable methods of birth control included oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-child bearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for > 1 year, was specified. Patients using hormonal forms of contraception were also willing to use a barrier method of contraception from screening through 30 days following the study period.
  5. Post-surgical patients who had been admitted to the PACU, and were expected to have acute pain requiring opioids for 24 - 72 hours after surgery.

Exclusion Criteria:

  1. Patients who had taken an opioid for more than 30 consecutive days, at a daily dose of 15 mg or more of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
  2. Patients who were currently taking monoamine oxidase inhibitors (MAOIs) or had taken MAOIs within 14 days of the first dose of study drug.
  3. Patients with current sleep apnea that had been documented by a sleep laboratory study or were on home continuous positive airway pressure (CPAP).
  4. Patients with an allergy or hypersensitivity to opioids.
  5. Patients who were currently taking monoamine oxidase inhibitors (MAOIs) or had taken MAOIs within 14 days of the first dose of study drug.
  6. Patients with current sleep apnea that had been documented by a sleep laboratory study or were on home continuous positive airway pressure (CPAP).
  7. Patients who were receiving oxygen therapy at the time of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02662764


Locations
Layout table for location information
United States, Alabama
Eliza Coffee Memorial Hospital
Florence, Alabama, United States, 35630
Shoals Medical Trials
Sheffield, Alabama, United States, 35660
United States, Arizona
Arizona Research Center
Phoenix, Arizona, United States, 85023
United States, Florida
Gulfcoast Research Associates
Sarasota, Florida, United States, 34232
G&G Research
Vero Beach, Florida, United States, 32960
Orthopedic Center of Vero Beach
Vero Beach, Florida, United States, 32960
Visions Clinical Research
Wellington, Florida, United States, 33414
United States, Georgia
Southeastern Center for Clinical Trials
Decatur, Georgia, United States, 30333
United States, Texas
Westside Surgical Hospital
Houston, Texas, United States, 77027
Hermann Drive Surgical Hospital
Houston, Texas, United States, 77089
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
AcelRx Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Pamela Palmer, MD, PhD AcelRx Pharmaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by AcelRx Pharmaceuticals, Inc.:
Statistical Analysis Plan  [PDF] June 10, 2017
Informed Consent Form  [PDF] January 19, 2016
Study Protocol  [PDF] January 13, 2016

Layout table for additonal information
Responsible Party: AcelRx Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02662764    
Other Study ID Numbers: IAP312
First Posted: January 26, 2016    Key Record Dates
Results First Posted: August 8, 2018
Last Update Posted: August 8, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Pain
Pain
Neurologic Manifestations
Sufentanil
Dsuvia
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics